🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million new cases annually. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the reality of rising global incidence, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Data and Global Access

According to data released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The research enrolled over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have voiced hope. Access to a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for public health efforts. This is considered essential to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea around the world.